Takeda has partnered with Koneksa Health to incorporate real-world data collection into its early-stage clinical trials, leveraging wearable sensors and biosensors to improve drug development. The collaboration aims to establish 'digital biomarkers' through Koneksa's real-world data software platform, facilitating the remote collection of continuous vital signs, activity levels, and sleep metrics.
Remote Data Collection for Enhanced Insights
The integration of Koneksa's technology allows Takeda to gather data that was previously difficult to obtain, offering a more comprehensive understanding of patient health outside of traditional clinical settings. This approach is intended to make clinical trials more patient-centric and enhance the overall efficiency of Takeda's pipeline development.
Elena Izmailova, Senior Director of Novel Data Streams and Devices at Takeda, stated, "Working with Koneksa enables us to take advantage of technologies and expertise that provide access to novel data streams and make our clinical trials more patient-centric. Koneksa’s end-to-end solution allows us to collect this data in our studies using Koneksa’s sensors and devices."
Strategic Digital Innovation
This deal represents a significant step for Koneksa and aligns with Takeda's broader strategy of seeking digital innovations in R&D. Takeda is also funding an early-phase trial to study the effects of activity, sleep, and diet on inflammatory bowel disease (IBD), integrating machine learning algorithms to gather insights.
Chris Benko, chief executive of Koneksa, noted, "Takeda has an exciting early pipeline of programmes as well as a deep commitment to ensuring that its therapies have the most meaningful impact to patients. This partnership provides Koneksa the opportunity to support the development of exciting medicines while broadening our bench of clinically validated sensor and device integrations."
